Apatinib Mesylate

Phase 3Small molecule

BBukwang Pharmaceutical

Apatinib Mesylate is one of 354 small molecule programs targeting Efficacy and Safety. It is currently in Phase 3.

Indications

Total Trials

Active Trials

353

Competitors

Pipeline

Status by Indication[3][1]

Indication

Efficacy and SafetyRecruiting

ChondrosarcomaActive, not recruiting

MeningiomaActive, not recruiting

Triple-Negative Breast CancerRecruiting

TreatmentRecruiting

Gastroesophageal Junction AdenocarcinomaRecruiting

Breast CancerRecruiting

Pancreatic CancerNot yet recruiting

Ovarian CancerNot yet recruiting

Gastric CancerUnknown status

Efficacy and SafetyPhase 3

Recruiting

ChondrosarcomaPreclinical

Active, not recruiting

MeningiomaPreclinical

Active, not recruiting

Triple-Negative Breast CancerPhase 2

Recruiting

TreatmentPreclinical

Recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Recruiting

Breast CancerPhase 3

Recruiting

Pancreatic CancerPhase 2

Not yet recruiting

Ovarian CancerPhase 3

Not yet recruiting

Gastric CancerPhase 3

Unknown status

Showing 10 of 12 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

3 2

Adenocard

Astellas

Preclinical

2 3

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 4

Spravato

WWim Janssens

Preclinical

2 5

Duragesic

CCephalon

Preclinical

1 6

Nubain

AAultman Health Foundation

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Rilvegostomig

AstraZeneca

Preclinical

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Not yet recruiting

Ovarian Cancer

NCT06539091

Phase 3Not yet recruiting

Ovarian Cancer

NCT06188455

Phase 2Recruiting

Small Cell Lung Cancer Limited Stage

NCT06483282

Q1 2027

N/ARecruiting

Treatment

NCT05751733

Q2 2027

Phase 2Recruiting

Gastroesophageal Junction Adenocarcinoma

NCT06415669

Q3 2027

Phase 2Not yet recruiting

Gastric Cancer

NCT05524974

Clinical

Trials by Indication[1]

Gastric Cancer14 trials

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Not yet recruiting·FFujian Medical University·Phase 2·NCT05524974·203 enrolled

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Completed·FFujian Cancer Hospital·Phase 2·NCT05223088·40 enrolled

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

Completed·BBukwang Pharmaceutical·Phase 1·NCT02711969·6 enrolled

Show 11 more trials

PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer

Unknown status·FFujian Cancer Hospital·N/A·NCT04174339·20 enrolled

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

Unknown status·FFudan University·Phase 2·NCT05095636·102 enrolled

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT05342389·68 enrolled

Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens

Unknown status·FFujian Cancer Hospital·Phase 2·NCT04089657·40 enrolled

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Unknown status·TThe First Affiliated Hospital of Xiamen University·Phase 1/2·NCT04572542·46 enrolled

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Unknown status·ZZhou Fuxiang·Phase 2·NCT04781686·35 enrolled

Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Not yet recruiting·FFujian Medical University·Phase 3·NCT07314203·118 enrolled

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Completed·FFujian Medical University·Phase 2·NCT04195828·106 enrolled

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Unknown status·RRemeGen Co., Ltd.·Phase 3·NCT04714190·351 enrolled

A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 4·NCT02776527·40 enrolled

A Prospective Study of the Efficacy and Safety of Apatinib Monotherapy as First-Line Treatment in Elderly Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting·TThe First Affiliated Hospital of Bengbu Medical University·Phase 2·NCT03219593·30 enrolled

Hepatocellular Carcinoma5 trials

A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin

Unknown status·—·Phase 2·NCT04850040·15 enrolled

Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

Active, not recruiting·SShanghai Zhongshan Hospital·Phase 2/3·NCT04521153·294 enrolled

Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT05613478·130 enrolled

Show 2 more trials

A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 1/2·NCT02772029·30 enrolled

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Technically Resectable Hepatocellular Carcinoma

Completed·ZZhejiang University·Phase 2·NCT04930315·78 enrolled

Apatinib3 trials

A Food Effect Study of Apatinib Mesylate in Healthy Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04341090·42 enrolled

Effect of Rifampicin on the Pharmacokinetics of Apatinib

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02836821·20 enrolled

Effect of Itraconazole on the Pharmacokinetics of Apatinib

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT02836171·20 enrolled

Breast Cancer3 trials

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Recruiting·FFujian Cancer Hospital·Phase 1/2·NCT05019690·29 enrolled

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06255392·200 enrolled

Breast Cancer Treatment Based on Organ-like Culture

Unknown status·XXijing Hospital··NCT03925233·300 enrolled

Ovarian Cancer3 trials

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 3·NCT06188455·37 enrolled

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

Unknown status·ZZhongshan Hospital Xiamen University·Phase 2·NCT04590625·58 enrolled

Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer

Not yet recruiting·—·Phase 3·NCT06539091·51 enrolled

33 more indications

Colorectal Cancer3 trials

Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer

Unknown status·ZZhongshan Hospital Xiamen University·Phase 1/2·NCT04202978·23 enrolled

Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)

Unknown status·SShenzhen People's Hospital·Phase 2·NCT03271255·80 enrolled

Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)

Suspended·SShenzhen People's Hospital·N/A·NCT03743428·40 enrolled

Nasopharyngeal Carcinoma3 trials

Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Completed·WWei Jiang·Phase 2·NCT04350190·25 enrolled

Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma

Unknown status·—·Phase 2·NCT03130270·29 enrolled

Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma

Unknown status·WWei Jiang·Phase 2·NCT03612219·240 enrolled

Osteosarcoma2 trials

Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma

Unknown status·PPeking University People's Hospital·Phase 2·NCT04351308·60 enrolled

Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma

Completed·PPeking University People's Hospital·N/A·NCT04690231·79 enrolled

Gastric Adenocarcinoma2 trials

Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT04948125·20 enrolled

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Unknown status·—·Phase 2·NCT04006821·30 enrolled

Melanoma2 trials

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT03955354·30 enrolled

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT04397770·40 enrolled

Small Cell Lung Cancer2 trials

Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer

Recruiting·YYunpeng Liu·N/A·NCT06480864·38 enrolled

Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT02995187·25 enrolled

Advanced Solid Tumor2 trials

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04322552·18 enrolled

A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04457180·18 enrolled

Non-Small Cell Lung Cancer2 trials

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04203485·762 enrolled

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Unknown status·PPeking University Third Hospital·Phase 1·NCT03050411·30 enrolled

Efficacy and Safety1 trial

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04342910·550 enrolled

Differentiated Thyroid Carcinoma1 trial

Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03167385·20 enrolled

Liver Cancer1 trial

The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer

Unknown status·—·Phase 2·NCT04204577·90 enrolled

Impaired Renal Function1 trial

A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04414852·24 enrolled

Bone Sarcoma1 trial

Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study

Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT03539172·61 enrolled

Lung Adenocarcinoma1 trial

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

Unknown status·—·Phase 1·NCT02691871·20 enrolled

Completed·—·Phase 2·NCT05235100·30 enrolled

Esophageal Squamous Cell Cancer1 trial

Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

Completed·YYuhong Li·Phase 2·NCT02976896·43 enrolled

Meningioma1 trial

Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults

Recruiting·—·N/A·NCT04501705·29 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma

Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT04440917·32 enrolled

Gastrointestinal1 trial

An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

Unknown status·HHarbin Medical University·Phase 2·NCT05225844·150 enrolled

Metastatic Head and Neck Cancer1 trial

A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers

Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT03096184·38 enrolled

Chondrosarcoma1 trial

Apatinib for Inoperable Advanced Chondrosarcoma

Completed·PPeking University People's Hospital·N/A·NCT04260113·40 enrolled

First-line Treatment1 trial

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Completed·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT05156970·81 enrolled

Camrelizumab1 trial

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT04683198·69 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT06415669·30 enrolled

Treatment1 trial

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Recruiting·XXiangya Hospital of Central South University·N/A·NCT05751733·258 enrolled

Squamous Cell Carcinoma1 trial

A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Completed·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT03267121·38 enrolled

Pancreatic Cancer1 trial

Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

Not yet recruiting·ZZhejiang University·Phase 2·NCT06759090·43 enrolled

Concurrent Chemoradiotherapy1 trial

Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT07357532·44 enrolled

Rhabdomyosarcoma1 trial

Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in Children

Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1/2·NCT03868852·48 enrolled

Small Cell Lung Cancer Limited Stage1 trial

A Single-arm, Prospective, Exploratory Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

Recruiting·JJin Ying·Phase 2·NCT06483282·38 enrolled

Triple-Negative Breast Cancer1 trial

A Prospective, Randomized, Open Label Clinical Study Evaluating Efficacy and Safety of Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic Triple Negative Breast Cancer

Recruiting·TThe First Affiliated Hospital of Bengbu Medical University·Phase 2·NCT05192798·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 71 trial records for Apatinib Mesylate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Apatinib Mesylate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Apatinib Mesylate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bukwang Pharmaceutical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBukwang Pharmaceutical

Apatinib Mesylate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Gastric Cancer14 trials

Hepatocellular Carcinoma5 trials

Apatinib3 trials

Breast Cancer3 trials

Ovarian Cancer3 trials

Colorectal Cancer3 trials

Nasopharyngeal Carcinoma3 trials

Osteosarcoma2 trials

Gastric Adenocarcinoma2 trials

Melanoma2 trials

Small Cell Lung Cancer2 trials

Advanced Solid Tumor2 trials

Non-Small Cell Lung Cancer2 trials

Efficacy and Safety1 trial

Differentiated Thyroid Carcinoma1 trial

Liver Cancer1 trial

Impaired Renal Function1 trial

Bone Sarcoma1 trial

Lung Adenocarcinoma1 trial

Adenoid Cystic Carcinoma1 trial

Soft Tissue Sarcoma1 trial

Preoperative1 trial

Esophageal Squamous Cell Cancer1 trial

Meningioma1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Gastrointestinal1 trial

Metastatic Head and Neck Cancer1 trial

Chondrosarcoma1 trial

First-line Treatment1 trial

Camrelizumab1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Treatment1 trial

Squamous Cell Carcinoma1 trial

Pancreatic Cancer1 trial

Concurrent Chemoradiotherapy1 trial

Rhabdomyosarcoma1 trial

Small Cell Lung Cancer Limited Stage1 trial

Triple-Negative Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News